Biomedical Research
Aclarion Expands Nociscan Use at Weill Cornell Medicine in New Trial on Disc Degeneration
Aclarion's second commercial agreement with Weill Cornell Medicine will deploy its Nociscan platform in a randomized controlled trial led by Dr. Roger Härtl, aiming to improve understanding and treatment of degenerative disc disease.
Ocumetics Reports Life-Changing Six-Month Results from First-in-Human Study of Accommodating Intraocular Lens
Ocumetics Technology Corp. announced that six-month postoperative results from its first-in-human study of the Ocumetics Accommodating Intraocular Lens show continued vision improvements and meaningful quality-of-life enhancements for patients, with plans to advance to Group Two surgeries.
Former NASA Engineer Releases Book on Anxiety Relief Through Energy Therapy
Mark L. Fox, former Space Shuttle Chief Engineer, has published a book promoting PEMF therapy as a drug-free solution for anxiety, chronic pain, and sleep disorders based on two decades of research.
Combined Biomarker Analysis Reveals Triple Heart Attack Risk in High-Risk Individuals
A new study shows that analyzing three specific biomarkers together can identify individuals with nearly triple the risk of heart attack, potentially enabling earlier intervention and personalized prevention strategies.
Oncotelic's Nanomedicine Platform Advances Cancer Treatment Through Enhanced Drug Delivery
Oncotelic Therapeutics' Deciparticle platform represents a significant advancement in nanomedicine that improves drug bioavailability and therapeutic effectiveness in oncology treatments.
New LED Therapy Shows Promise in Targeting Cancer Cells While Preserving Healthy Tissues
Researchers have developed a novel LED-based cancer treatment that selectively destroys cancer cells while minimizing damage to healthy tissues, potentially offering a more precise alternative to conventional therapies like chemotherapy and radiation.
Skychem Group Expands Global Chemical Solutions with Three Decades of Industry Expertise
Skychem Group leverages over 30 years of chemical industry experience to expand into biomedicine and new materials while maintaining global operations across 70 countries.
BioMed X Launches Women's Health R&D Accelerator with Gates Foundation Support
BioMed X has launched XFem Labs, a women's health research accelerator in Heidelberg focused on developing non-hormonal contraceptive solutions to address global access barriers and high discontinuation rates of current methods.
Hong Kong and GBA Cities Forge Biomedical Partnership Driving Global Innovation Leadership
Hong Kong's biomedical sector has grown nearly 30% in the past decade, with collaborative efforts across the Greater Bay Area positioning the region as a global biotech innovation hub through financial resources, clinical trial capabilities, and cross-border partnerships.
New Research Identifies SOX6 Protein as Potential Key to Myelin Repair in Multiple Sclerosis
Groundbreaking research published in Cell reveals that targeting the SOX6 protein could enable myelin repair in multiple sclerosis patients, potentially opening new therapeutic avenues for the neurodegenerative disease.
CD BioGlyco Expands Glycobiology Research Capabilities with Custom Glycoconjugate Synthesis Service
CD BioGlyco's new custom glycoconjugate synthesis service enables researchers to study glycan functions in cell recognition and immune responses, advancing biomedical research capabilities.
BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery
BioMed X and Novo Nordisk have partnered to tackle the challenge of oral peptide drug delivery, aiming to improve patient compliance and treatment efficacy through innovative formulation technologies.
Quantum BioPharma's PET Tracer Shows Promise in Monitoring Myelin Integrity in Multiple Sclerosis
Quantum BioPharma Ltd.'s collaboration with Massachusetts General Hospital has yielded a PET tracer capable of detecting MS lesions invisible to conventional MRI, marking a significant advancement in the monitoring and treatment of multiple sclerosis.
Curebound Aims to Accelerate Cancer Cures Amid NIH Funding Cuts
Curebound, under the leadership of COO Karen Hooper, is intensifying efforts to fund innovative cancer research, especially critical in light of recent NIH funding cuts, to accelerate cures within our lifetime.
University of Plymouth Researchers Identify Proteins Linked to Brain Tumor Growth
Researchers at the University of Plymouth have discovered proteins crucial for the growth of common brain tumors, paving the way for less invasive treatments.
SeaStar Medical Advances Organ-Saving Therapies for Critically Ill Patients
SeaStar Medical is developing innovative medical devices targeting acute kidney injury, leveraging FDA Breakthrough Device Status to potentially transform treatment for critically ill patients across multiple serious conditions.
Clene Inc. Advances CNM-Au8 Toward Potential Accelerated Approval for ALS
Clene Inc. reports promising progress on its CNM-Au8 therapy for ALS, with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway, supported by significant survival data and reduced expenses.
Clene Inc. Advances Promising Therapy for ALS, Targets Accelerated FDA Approval
Clene Inc. reports significant progress on CNM-Au8, a potential breakthrough therapy for amyotrophic lateral sclerosis (ALS), with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway in Q4 2025. New data demonstrates improved patient survival and neurological repair.
BioRestorative Therapies Advances Stem Cell Treatments for Chronic Pain and Metabolic Diseases
BioRestorative Therapies is developing innovative stem cell therapies targeting chronic lower back pain, obesity, and type 2 diabetes, potentially offering new treatment options for millions suffering from these conditions.
DoD Awards $876,000 Grant to Advance Lung Cancer Biomarker Research at Cedars-Sinai
The U.S. Department of Defense has provided funding to Cedars-Sinai Medical Center to support biomarker research for Kairos Pharma's experimental lung cancer treatment, focusing on identifying potential early intervention strategies for patients developing resistance to current therapies.